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Letter to the Editor
Urgent need for demonstration projects
in Portugal to produce pre-exposure
prophylaxis-related data
Dear Editor,
In Portugal, the HIV epidemic is concentrated in key
populations (KP), e.g. people who inject drugs, men
having sex with men (MSM) as well as male/female
sex workers.1–3 In the last decade, HIV prevention
activities for KPs were implemented, such as
CheckpointLX. This community-based facility in
Lisbon, run by the non-governmental organization
(NGO) GAT, oﬀers, in an MSM-friendly atmosphere,
free testing for HIV and other sexually transmitted
infections (STIs), medical consultations, and peer coun-
seling. Despite these initiatives, the epidemic is still
uncontrolled, in particular among MSM, whose inci-
dence rate was recently estimated at 2.8/100 person-
years.4 Consequently, Portugal urgently needs add-
itional strategies to control HIV.
Oral pre-exposure prophylaxis (PrEP) is a preven-
tion tool, directed at seronegative people highly
exposed to HIV. Numerous clinical trials showed that
the combination of antiretroviral drugs tenofovir diso-
proxil fumarate (TDF) and emtricitabine (FTC) pro-
tected participants who took the drugs as
recommended from HIV infection, with a very high
eﬃcacy (>90%). The level of adherence was the main
factor associated with PrEP eﬃcacy.5 PrEP is now rec-
ommended by many organizations, in the framework of
a combination prevention package. As of March 2016,
Truvada has been authorized as a preventative bio-
medical intervention in six countries worldwide (i.e.
Canada, Israel, France, South Africa, Kenya, and the
United States).6
Despite these encouraging results, many political,
legal, economic, and social issues regarding PrEP
need to be better understood. The WHO encourages
countries to implement trials, in particular demon-
stration projects, to identify how to include PrEP
in real life. Each country must now identify the
best strategy for the introduction and the scaling-
up of PrEP.
Several PrEP initiatives have recently been launched
in various cities around the world (e.g. San Francisco,
Baltimore, Sao Paulo, and Amsterdam). In Europe, the
Netherlands and Belgium initiated demonstration pro-
jects in 2015 (AmPREP and Be-PrEP-ared). In add-
ition, the British PROUD study is still going on as an
open-label project, oﬀering PrEP to participants of
both arms. Finally, Paris will also be launching its ini-
tiative in the next few months.
Regarding PrEP in Portugal, data are scarce. A
PrEP acceptability study, conducted in Lisbon during
the 2014 gay pride fair and involving 110 HIV-negative
MSM, concluded that 57% of participants would be
willing to take PrEP if available in Portugal and 66%
would participate in a clinical trial in Portugal. Among
the MSM of the Lisbon cohort (2183 individuals
between 2011 and 2014), 80% were eligible for PrEP
according to the Centres for Disease Control and
Prevention recommendations. The country now needs
a demonstration project to identify the target and the
best way to deliver PrEP. Considering the role of civil
society in HIV prevention, it would be essential to
involve the community and community-based NGOs
in this process, ensuring a good acceptability of PrEP
in the community. Community-based facilities, like the
CheckpointLX, would be good settings to implement a
PrEP demonstration project for MSM. There is now an
urgent need to produce data about PrEP in Portugal
and consider the introduction of PrEP for the most
at-risk seronegative people!
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